
Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).






























